Precision Oncology: How DNA Testing Changes Cancer Treatment | Geneomm Medical Center

Genomic Profiling vs. Traditional Biopsy
While a traditional biopsy tells us where the cancer came from (e.g., breast or lung), genomic profiling looks at the DNA mutations driving that specific tumor. This allows us to understand the “engine” of the cancer rather than just its location.
The “Lock and Key” Approach to Targeted Therapy
Many modern cancer drugs are designed to fit into specific genetic mutations like a key into a lock. If your tumor has a specific mutation (like HER2 or EGFR), we can use drugs that attack only those cells, leaving healthy cells alone.
Reducing Side Effects Through Precision
Because targeted therapies are more specific than traditional chemotherapy, patients often experience fewer systemic side effects, such as hair loss or extreme nausea, leading to a better quality of life during treatment.
Real Stories: Success in Personalized Care
We share how patients with advanced-stage cancers have seen significant remission because we identified a rare mutation that responded to a newly approved, specific medication.

Genomic Profiling vs. Traditional Biopsy
While a traditional biopsy tells us where the cancer came from (e.g., breast or lung), genomic profiling looks at the DNA mutations driving that specific tumor. This allows us to understand the “engine” of the cancer rather than just its location.
The “Lock and Key” Approach to Targeted Therapy
Many modern cancer drugs are designed to fit into specific genetic mutations like a key into a lock. If your tumor has a specific mutation (like HER2 or EGFR), we can use drugs that attack only those cells, leaving healthy cells alone.
Reducing Side Effects Through Precision
Because targeted therapies are more specific than traditional chemotherapy, patients often experience fewer systemic side effects, such as hair loss or extreme nausea, leading to a better quality of life during treatment.
Real Stories: Success in Personalized Care
We share how patients with advanced-stage cancers have seen significant remission because we identified a rare mutation that responded to a newly approved, specific medication.